Does CASIMERSEN Cause Poor venous access? 101 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 101 reports of Poor venous access have been filed in association with CASIMERSEN (AMONDYS 45). This represents 13.2% of all adverse event reports for CASIMERSEN.
101
Reports of Poor venous access with CASIMERSEN
13.2%
of all CASIMERSEN reports
0
Deaths
5
Hospitalizations
How Dangerous Is Poor venous access From CASIMERSEN?
Of the 101 reports, 5 (5.0%) required hospitalization.
Is Poor venous access Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CASIMERSEN. However, 101 reports have been filed with the FAERS database.
What Other Side Effects Does CASIMERSEN Cause?
Product dose omission issue (253)
No adverse event (166)
Device issue (76)
Intentional dose omission (74)
Malaise (36)
Pyrexia (31)
Covid-19 (29)
Influenza (18)
Pneumonia (17)
Product distribution issue (17)
What Other Drugs Cause Poor venous access?
VEDOLIZUMAB (1,043)
INFLIXIMAB (917)
INFLIXIMAB-DYYB (782)
ECULIZUMAB (555)
HUMAN IMMUNOGLOBULIN G (504)
NATALIZUMAB (422)
RITUXIMAB (299)
TOCILIZUMAB (287)
METHOTREXATE (257)
ABATACEPT (249)
Which CASIMERSEN Alternatives Have Lower Poor venous access Risk?
CASIMERSEN vs CASIRIVIMAB
CASIMERSEN vs CASIRIVIMAB\IMDEVIMAB
CASIMERSEN vs CASPOFUNGIN
CASIMERSEN vs CATEQUENTINIB
CASIMERSEN vs CC-4047